Pentoxifylline in patients with COVID-19 and with liver cirrhosis or metabolic dysfunction-associated steatotic liver disease: Emerging insights.
- DOI
- 10.3892/br.2026.2150
- Published
- 2026 Jun
- Container
- Biomedical reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3892/br.2026.2150,
title = {Pentoxifylline in patients with COVID-19 and with liver cirrhosis or metabolic dysfunction-associated steatotic liver disease: Emerging insights.},
author = {Jiménez-Luevano MÁ and Jiménez-Partida AE and Jiménez-Partida MA and Del Rio-Hidalgo RF and Bravo-Hernández A and Villaseñor-García MM and Bravo-Cuellar A and Hernández-Flores G},
year = {2026},
journal = {Biomedical reports},
doi = {10.3892/br.2026.2150},
url = {https://doi.org/10.3892/br.2026.2150}
}RIS
TY - JOUR TI - Pentoxifylline in patients with COVID-19 and with liver cirrhosis or metabolic dysfunction-associated steatotic liver disease: Emerging insights. AU - Jiménez-Luevano MÁ AU - Jiménez-Partida AE AU - Jiménez-Partida MA AU - Del Rio-Hidalgo RF AU - Bravo-Hernández A AU - Villaseñor-García MM AU - Bravo-Cuellar A AU - Hernández-Flores G PY - 2026 JO - Biomedical reports DO - 10.3892/br.2026.2150 UR - https://doi.org/10.3892/br.2026.2150 ER -
APA
MÁ, J., AE, J., MA, J., RF, D. R., A, B., MM, V., A, B., & G, H. (2026). Pentoxifylline in patients with COVID-19 and with liver cirrhosis or metabolic dysfunction-associated steatotic liver disease: Emerging insights.. Biomedical reports. https://doi.org/10.3892/br.2026.2150
Source records
- pubmed · retrieved 2026-11-10T16:51:20.318Z